Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies
Originally published on LinkedIn on October 7, 2025
This week, as the lights flicker in Washington and the nation feels the uncertainty of a government shutdown, the desert sun in Arizona seems to shine even brighter. At the Alliance for Regenerative Medicine’s Meeting on the Mesa, the cell and gene therapy community is alive with optimism, purpose, and momentum.
Inside the conference halls, the conversations are rich with possibility—how to accelerate clinical development, expand access, and build systems that can weather disruption. It’s a striking contrast: one part of our national infrastructure has slowed, while another is surging forward through collaboration and creativity.
That contrast is revealing. Progress in advanced therapies requires designing for resilience.
Resilience in Real Time
For those of us working in cell and gene therapy, moments like this remind us how interconnected science and systems truly are. The government shutdown is more than a policy event—it’s a stress test. It exposes where our infrastructure depends too heavily on stability and where it’s flexible enough to adapt.
And yet, progress continues. Across the country, research teams are still collecting cells, running assays, and analyzing data. Partnerships are forming. Trials are enrolling. Innovation moves forward not because the path is smooth, but because the people leading it refuse to stop.
That’s the defining strength of this field: its ability to turn disruption into determination.
Designing for Continuity and Connection
The regenerative medicine community has learned to build for resilience. From supply chains to regulatory frameworks, we’re learning to design continuity into the system—to ensure that therapies, trials, and patients are not left waiting when external pressures rise.
This spirit of adaptability is at the heart of what’s happening here at the Mesa. The connections being made this week represent more than professional alignment; they’re the foundation for shared problem-solving across an ecosystem that depends on partnership.
Progress in advanced therapies isn’t a solo effort—it’s a collective design project. One where data, infrastructure, and collaboration form the true scaffolding of innovation.
Access as the Engine of Progress
Resilience exists for a purpose: to create access that endures. Every innovation ultimately leads to a patient, and every system we design should be built with that patient in mind.
When systems stall—whether due to funding gaps, logistics, or geography—patients feel it first. That’s why access and scalability are not just operational priorities; they are the moral architecture of this field.
I often think of patient access and market scalability as the twin rails for progress—the structure that supports not only innovation, but the shared progress that turns science into solutions. Together, they create the space for the leap of faith every breakthrough requires: the courage to build systems that don’t yet exist, but must.
A Blueprint for What Comes Next
I’m honored to be speaking here on Wednesday morning here, about one such example of innovation—scaling access through a mobile model for leukapheresis. It’s a new approach to bringing regulated, high-quality cell collection directly to patients and communities, especially those historically underrepresented in clinical trials.
It’s one idea among many that share a common purpose: to ensure the future of cell and gene therapy is not only innovative, but inclusive and sustainable.
The government shutdown will pass. But the lesson it offers will stay with us. Progress doesn’t wait for perfect conditions—it depends on the systems we build, the people we trust, and the collective resilience we cultivate along the way.
When the lights flicker, the work continues. That’s the power of progress when systems stand still.
